Talis Biomedical (TLIS) AI Stock Analysis

• Market Cap: $47.53M
• Dividend Yield: N/A
• Average Volume (3M): 160.00
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 99
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -28.02
• Shares Outstanding: 1,822,820
• 10 Day Avg. Volume: 126
• 30 Day Avg. Volume: 160
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 29 Underperform
• Price Target: ―

Talis Biomedical's stock is significantly impacted by its poor financial performance, marked by declining revenues and persistent losses. The technical indicators reflect a bearish trend, while the negative P/E ratio highlights valuation concerns. These factors collectively suggest a high-risk investment with limited short-term recovery potential.

Talis Biomedical Business Overview & Revenue Model

Company Description

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

How the Company Makes Money

Talis Biomedical generates revenue primarily through the sale of its diagnostic testing products. The company's core revenue stream comes from its point-of-care testing solutions that are sold to clinics, hospitals, and other healthcare facilities. These products are designed to offer quick and reliable test results, thus addressing the need for timely diagnostics in patient care. Additionally, Talis may engage in partnerships and collaborations with other healthcare organizations and research institutions, which can also contribute to its earnings through joint development agreements, licensing deals, or co-marketing strategies. The focus on delivering innovative and efficient diagnostic tools helps Talis Biomedical maintain its competitive edge and attract a steady customer base.

Talis Biomedical Financial Statement Overview

Summary

Talis Biomedical is facing significant financial challenges, with consistent net losses and negative cash flow. Despite improvements in gross profit margin and a sound equity base, the company struggles with declining revenues and high operational costs. These factors pose substantial risks to its financial health.

Income Statement

Talis Biomedical has experienced a declining revenue trend, with a significant drop from $10.94 million in 2020 to $412,000 in 2023. The gross profit margin improved to 90% in 2023, indicating cost efficiencies, but the company remains unprofitable with a net loss margin of -15055%. EBIT and EBITDA margins are highly negative, pointing to ongoing operational challenges.

Balance Sheet

The balance sheet reflects a high equity ratio of 73% in 2023, showing a solid equity base relative to assets. However, the debt-to-equity ratio increased slightly to 0.28, indicating a manageable but present level of leverage. The company has ample cash reserves, but the consistent losses could deplete resources over time.

Cash Flow

Operating cash flow has been negative, reflecting cash outflows exceeding inflows, with a free cash flow of -$53.73 million in 2023. The free cash flow to net income ratio is unfavorable, indicating inefficiencies in converting net income into cash. The company has yet to generate positive cash flow from operations or investments.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	412.00K	3.65M	0.00	10.94M	3.98M
Gross Profit	371.00K	-4.74M	-2.62M	10.94M	3.98M
EBITDA	-66.05M	-106.31M	-191.82M	-90.42M	-25.97M
Net Income	-62.01M	-110.89M	-190.46M	-91.08M	-27.43M
Balance Sheet
Total Assets	94.67M	169.29M	265.83M	198.41M	25.73M
Cash, Cash Equivalents and Short-Term Investments	76.73M	130.19M	232.54M	138.48M	21.60M
Total Debt	19.67M	33.58M	13.98M	693.00K	0.00
Total Liabilities	25.56M	42.55M	31.85M	306.98M	46.87M
Stockholders Equity	69.12M	126.74M	233.98M	-108.57M	-21.14M
Cash Flow
Free Cash Flow	-53.73M	-101.75M	-174.25M	-95.22M	-24.90M
Operating Cash Flow	-53.24M	-100.14M	-171.38M	-87.02M	-24.33M
Investing Cash Flow	-486.00K	-1.61M	-2.87M	-8.20M	-578.00K
Financing Cash Flow	33.00K	406.00K	234.43M	246.75M	39.61M

Talis Biomedical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLIS, the sentiment is Positive. The current price of 1.5 is below the 20-day moving average (MA) of 1.52, above the 50-day MA of 1.49, and below the 200-day MA of 1.57, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.04 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TLIS.

Talis Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DGX	73 Outperform	$21.12B	22.58	13.13%	1.63%	12.58%	13.00%
NTRA	70 Neutral	$22.38B	-84.66	-20.32%	―	44.38%	22.87%
QDEL	55 Neutral	$1.96B	-4.51	-16.70%	―	-3.00%	76.48%
OSUR	50 Neutral	$232.58M	-4.70	-13.40%	―	-49.35%	-285.61%
VERU	47 Neutral	$54.24M	-1.95	-116.97%	―	-52.76%	43.40%
TLIS	29 Underperform	$47.53M	―	-89.71%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%